Do analysts recommend UTZ or CPHI?

Utz Brands presently has a consensus price target of $13.39, indicating a potential downside of 5.56%. Given Utz Brands' stronger consensus rating and higher possible upside, research analysts plainly believe Utz Brands is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utz Brands 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is UTZ or CPHI more profitable?

Utz Brands has a net margin of -0.58% compared to China Pharma's net margin of -85.56%. Utz Brands' return on equity of 8.61% beat China Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Utz Brands -0.58% 8.61% 4.17% China Pharma -85.56% -63.93% -31.42%

Does the media prefer UTZ or CPHI?

In the previous week, Utz Brands had 10 more articles in the media than China Pharma. MarketBeat recorded 11 mentions for Utz Brands and 1 mentions for China Pharma. Utz Brands' average media sentiment score of 0.14 beat China Pharma's score of 0.00 indicating that Utz Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Utz Brands 1 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend INDP or CPHI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor INDP or CPHI?

In the previous week, Indaptus Therapeutics and Indaptus Therapeutics both had 1 articles in the media. Indaptus Therapeutics' average media sentiment score of 1.95 beat China Pharma's score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer KROS or CPHI?

Keros Therapeutics currently has a consensus target price of $20.40, indicating a potential upside of 101.78%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Keros Therapeutics is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor KROS or CPHI?

In the previous week, Keros Therapeutics had 7 more articles in the media than China Pharma. MarketBeat recorded 8 mentions for Keros Therapeutics and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.00 beat Keros Therapeutics' score of -0.49 indicating that China Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CPHI or RNA?

Avidity Biosciences has a consensus target price of $67.60, suggesting a potential upside of 496.65%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avidity Biosciences 1 Sell rating(s) 12 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.28

Does the media favor CPHI or RNA?

In the previous week, China Pharma and China Pharma both had 1 articles in the media. Avidity Biosciences' average media sentiment score of 1.02 beat China Pharma's score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ACOG or CPHI?

Alpha Cognition presently has a consensus price target of $16.00, suggesting a potential upside of 89.80%. Given Alpha Cognition's stronger consensus rating and higher possible upside, equities research analysts plainly believe Alpha Cognition is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to ACOG or CPHI?

In the previous week, Alpha Cognition had 4 more articles in the media than China Pharma. MarketBeat recorded 5 mentions for Alpha Cognition and 1 mentions for China Pharma. Alpha Cognition's average media sentiment score of 0.91 beat China Pharma's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

China Pharma (CPHI) Competitors

$1.14 +0.03 (+2.70%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$1.18 +0.04 (+3.51%)

As of 08/3/2026 08:00 PM Eastern

Compare

CPHI vs. UTZ, INDP, KROS, RNA, and ACOG

Should you buy China Pharma stock or one of its competitors? MarketBeat compares China Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with China Pharma include Utz Brands (UTZ), Indaptus Therapeutics (INDP), Keros Therapeutics (KROS), Avidity Biosciences (RNA), and Alpha Cognition (ACOG).

How does China Pharma compare to Utz Brands?

Utz Brands (NYSE:UTZ) and China Pharma (NYSE:CPHI) are related companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Utz Brands presently has a consensus price target of $13.39, indicating a potential downside of 5.56%. Given Utz Brands' stronger consensus rating and higher possible upside, research analysts plainly believe Utz Brands is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Utz Brands	1 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Utz Brands has higher revenue and earnings than China Pharma. Utz Brands is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Utz Brands	$1.44B	1.42	$800K	-$0.10	N/A
China Pharma	$3.99M	11.57	-$3.08M	-$0.55	N/A

In the previous week, Utz Brands had 10 more articles in the media than China Pharma. MarketBeat recorded 11 mentions for Utz Brands and 1 mentions for China Pharma. Utz Brands' average media sentiment score of 0.14 beat China Pharma's score of 0.00 indicating that Utz Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Utz Brands	1 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Utz Brands has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

96.0% of Utz Brands shares are owned by institutional investors. 12.7% of Utz Brands shares are owned by insiders. Comparatively, 6.4% of China Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Utz Brands has a net margin of -0.58% compared to China Pharma's net margin of -85.56%. Utz Brands' return on equity of 8.61% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Utz Brands	-0.58%	8.61%	4.17%
China Pharma	-85.56%	-63.93%	-31.42%

Summary

Utz Brands beats China Pharma on 13 of the 16 factors compared between the two stocks.

How does China Pharma compare to Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and China Pharma (NYSE:CPHI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

7.1% of Indaptus Therapeutics shares are held by institutional investors. 9.9% of Indaptus Therapeutics shares are held by insiders. Comparatively, 6.4% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Indaptus Therapeutics and Indaptus Therapeutics both had 1 articles in the media. Indaptus Therapeutics' average media sentiment score of 1.95 beat China Pharma's score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Indaptus Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
China Pharma	-85.56%	-63.93%	-31.42%

China Pharma has higher revenue and earnings than Indaptus Therapeutics. China Pharma is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
China Pharma	$3.99M	11.57	-$3.08M	-$0.55	N/A

Indaptus Therapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Indaptus Therapeutics beats China Pharma on 7 of the 12 factors compared between the two stocks.

How does China Pharma compare to Keros Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and China Pharma (NYSE:CPHI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

71.6% of Keros Therapeutics shares are owned by institutional investors. 12.6% of Keros Therapeutics shares are owned by insiders. Comparatively, 6.4% of China Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Keros Therapeutics currently has a consensus target price of $20.40, indicating a potential upside of 101.78%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Keros Therapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Keros Therapeutics has higher revenue and earnings than China Pharma. Keros Therapeutics is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.82	$87.01M	-$3.01	N/A
China Pharma	$3.99M	11.57	-$3.08M	-$0.55	N/A

In the previous week, Keros Therapeutics had 7 more articles in the media than China Pharma. MarketBeat recorded 8 mentions for Keros Therapeutics and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.00 beat Keros Therapeutics' score of -0.49 indicating that China Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

China Pharma has a net margin of -85.56% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -17.04% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
China Pharma	-85.56%	-63.93%	-31.42%

Keros Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

Summary

Keros Therapeutics beats China Pharma on 10 of the 16 factors compared between the two stocks.

How does China Pharma compare to Avidity Biosciences?

China Pharma (NYSE:CPHI) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Avidity Biosciences has a consensus target price of $67.60, suggesting a potential upside of 496.65%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.28

China Pharma has a net margin of -85.56% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

China Pharma has higher earnings, but lower revenue than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	11.57	-$3.08M	-$0.55	N/A
Avidity Biosciences	$36.68M	5.28	-$322.30M	-$0.97	N/A

In the previous week, China Pharma and China Pharma both had 1 articles in the media. Avidity Biosciences' average media sentiment score of 1.02 beat China Pharma's score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

China Pharma has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Avidity Biosciences has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Summary

China Pharma and Avidity Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does China Pharma compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and China Pharma (NYSE:CPHI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

In the previous week, Alpha Cognition had 4 more articles in the media than China Pharma. MarketBeat recorded 5 mentions for Alpha Cognition and 1 mentions for China Pharma. Alpha Cognition's average media sentiment score of 0.91 beat China Pharma's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Cognition presently has a consensus price target of $16.00, suggesting a potential upside of 89.80%. Given Alpha Cognition's stronger consensus rating and higher possible upside, equities research analysts plainly believe Alpha Cognition is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

China Pharma has lower revenue, but higher earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	17.96	-$20.67M	-$1.35	N/A
China Pharma	$3.99M	11.57	-$3.08M	-$0.55	N/A

Alpha Cognition has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

China Pharma has a net margin of -85.56% compared to Alpha Cognition's net margin of -232.23%. Alpha Cognition's return on equity of -58.35% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
China Pharma	-85.56%	-63.93%	-31.42%

Summary

Alpha Cognition beats China Pharma on 9 of the 14 factors compared between the two stocks.

Get China Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPHI vs. The Competition

Export

Metric	China Pharma	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$46.20M	$11.61B	$6.86B	$23.73B
Dividend Yield	N/A	2.73%	2.60%	4.21%
P/E Ratio	-2.07	793.98	280.74	31.49
Price / Sales	11.57	731.95	588.16	14.43
Price / Cash	N/A	14.82	28.64	18.72
Price / Book	1.63	10.39	11.02	4.83
Net Income	-$3.08M	$2.80B	$3.48B	$1.07B
7 Day Performance	-12.31%	0.76%	0.81%	0.34%
1 Month Performance	58.77%	-3.80%	-4.15%	0.59%
1 Year Performance	-28.75%	154.73%	61.47%	18.76%

China Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPHI China Pharma	N/A	$1.14 +2.7%	N/A	-30.5%	$46.20M	$3.99M	N/A	250	Gap Up
UTZ Utz Brands	1.717 of 5 stars	$14.15 +0.6%	$13.39 -5.4%	+3.7%	$2.02B	$1.44B	N/A	3,300	Upcoming Earnings
INDP Indaptus Therapeutics	0.9028 of 5 stars	$1.44 -20.9%	N/A	-82.1%	$206.10M	N/A	N/A	6	Positive News Gap Up High Trading Volume
KROS Keros Therapeutics	2.3633 of 5 stars	$10.22 +2.5%	$20.40 +99.6%	-29.4%	$197.33M	$33.18M	N/A	100	News Coverage Earnings Report Upcoming Earnings
RNA Avidity Biosciences	2.4493 of 5 stars	$11.46 +2.5%	$67.60 +489.9%	-68.5%	$196.04M	$36.68M	N/A	190	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CPHI) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

China Pharma (CPHI) Competitors

CPHI vs. UTZ, INDP, KROS, RNA, and ACOG

How does China Pharma compare to Utz Brands?

Summary

How does China Pharma compare to Indaptus Therapeutics?

Summary

How does China Pharma compare to Keros Therapeutics?

Summary

How does China Pharma compare to Avidity Biosciences?

Summary

How does China Pharma compare to Alpha Cognition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

China Pharma (CPHI) Competitors

CPHI vs. UTZ, INDP, KROS, RNA, and ACOG

How does China Pharma compare to Utz Brands?

Do analysts recommend UTZ or CPHI?

Which has preferable valuation and earnings, UTZ or CPHI?

Does the media prefer UTZ or CPHI?

Which has more volatility and risk, UTZ or CPHI?

Do institutionals and insiders believe in UTZ or CPHI?

Is UTZ or CPHI more profitable?

Summary

How does China Pharma compare to Indaptus Therapeutics?

Do insiders & institutionals hold more shares of INDP or CPHI?

Does the media favor INDP or CPHI?

Is INDP or CPHI more profitable?

Which has better valuation and earnings, INDP or CPHI?

Which has more volatility & risk, INDP or CPHI?

Do analysts recommend INDP or CPHI?

Summary

How does China Pharma compare to Keros Therapeutics?

Do insiders and institutionals believe in KROS or CPHI?

Do analysts prefer KROS or CPHI?

Which has preferable valuation and earnings, KROS or CPHI?

Does the media favor KROS or CPHI?

Is KROS or CPHI more profitable?

Which has more volatility and risk, KROS or CPHI?

Summary

How does China Pharma compare to Avidity Biosciences?

Do analysts prefer CPHI or RNA?

Is CPHI or RNA more profitable?

Which has stronger earnings and valuation, CPHI or RNA?

Does the media favor CPHI or RNA?

Which has more risk & volatility, CPHI or RNA?

Summary

How does China Pharma compare to Alpha Cognition?

Does the media refer more to ACOG or CPHI?

Do analysts recommend ACOG or CPHI?

Which has better earnings & valuation, ACOG or CPHI?

Which has more volatility and risk, ACOG or CPHI?

Is ACOG or CPHI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools